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Abstract
 
Killer cell Ig-like receptors (KIRs) regulate the function of human natural killer and T cell sub-
sets. A feature of the KIR locus is the clustering of homologous genes encoding for inhibitory
and activating KIR. Inhibitory and activating KIR differ for ligand specificities and/or affini-
ties. In particular, we show here with KIR tetramers that activating KIR2DS2 does not bind
HLA-Cw3 molecules recognized by inhibitory KIR2DL2, despite 99% extracellular amino
acid identity. We also report the 2.3-Å structure of KIR2DS2, which reveals subtle displace-
ments of two residues (Tyr
 
45
 
 and Gln
 
71
 
) involved in the interaction of KIR2DL2 with
HLA-Cw3. These results show that KIR molecules cannot tolerate any variability in their
three-dimensional structure without altering their MHC class I recognition capacities. There-
fore, the mode of recognition used by KIR largely differs from the conformational changes that
characterize T cell receptor or NKG2D interaction with their respective ligands.
Key words: KIR • crystal structure
 
Introduction
 
Eight genes encoding for inhibitory KIR (KIR-L) and six
genes encoding for activating KIR (KIR-S) are clustered in
the human chromosome 19q13.4 within the leukocyte
receptor complex (1). KIR can harbor two (KIR2D) or
three (KIR3D) extracellular C2-type Ig-like domains. The
KIR-L recognition of HLA class I allotypes is determined
by the amino acids belonging to the COOH-terminal por-
tion of the MHC class I 
 
 
 
1 helix (1). In particular, the rec-
ognition of inhibitory KIR2D is dictated to a large extent
by the nature of the MHC class I amino acid present at po-
sition 80; KIR2DL1 (CD158a) recognizes HLA-C charac-
terized by a Lys
 
80
 
 residue (HLA-Cw4 and related alleles),
whereas KIR2DL2 (CD158b1) and KIR2DL3 (CD158b2)
allelic forms recognize HLA-C with an Asn
 
80
 
 residue
(HLA-Cw3 and related alleles).
In contrast to KIR-L, knowledge of the ligand specific-
ity of KIR-S is limited. Using KIR-S/Fc constructs and a
flow cytometry assay, only a weak interaction between
KIR2DS1 (CD158h) and Lys
 
80
 
 HLA-C molecules has
been reported, despite its homology to KIR2DL1 (2). The
same approach failed to detect an interaction between
KIR2DS2 and Asn
 
80
 
 HLA-C, although KIR2DS2 is highly
homologous to KIR2DL2 and KIR2DL3 (3, 4). So far,
only KIR-L three-dimensional structures have been re-
solved (KIR2DL1, KIR2DL2, and KIR2DL3; references
5–7), free or complexed to HLA-C ligands (KIR2DL2–
HLA-Cw3, KIR2DL1–HLA-Cw4; references 8, 9). We
report here the first crystal structure of an activating KIR,
KIR2DS2 (CD158j), at 2.3-Å resolution.
 
Materials and Methods
 
Generation of KIR Tetrameric Complexes.
 
cDNA encoding the
entire extracellular domain of KIR2DS2, KIR2DL1, and
KIR2DL3 were amplified by PCR using Pwo DNA polymerase
(Roche) and cloned into PLM-1 plasmid in frame with a se-
quence encoding a biotinylation signal. Soluble KIR proteins
were produced as described previously (9), and biotinylated with
biotin ligase BirA (Avidity). Soluble KIR tetramers were formed
by incubating the biotinylated KIR with PE-coupled streptavidin
(Molecular Probes) at a molar ratio of 4:1.
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Binding Assay.
 
The HLA-A, -B, and -C negative mutant B
lymphoblastoid cell line L.721.221 and its HLA-Cw3
 
 
 
 and
-Cw4
 
 
 
 transfectants were provided by R. Biassoni (Center for
Advanced Biotechnology, Genova, Italy). Cells were incubated
for 1 h at 4
 
 
 
C with purified KIR tetramers. Fluorescence was an-
alyzed by flow cytometry on a FACScan™ (Becton Dickinson).
The ability of anti–MHC class I mAb to inhibit tetramer binding
was assayed by preincubating cells with 6a4 mAb (provided by A.
Moretta, School of Medicine, Genova University, Genova, Italy)
for 30 min at 4
 
 
 
C.
 
Crystallization, Data Collection, Phase Determination, and Refine-
ment.
 
A purified and renatured soluble form of truncated hu-
man KIR2DS2 (Arg
 
6
 
 to Thr
 
200
 
) was prepared according to Fan et
al. (9), and crystallized at 20
 
 
 
C in a 2–4-
 
 
 
l hanging drop contain-
ing a 1:1 mixture of protein solution (13 mg/ml KIR2DS2 in 50
mM Tris, pH 8, and 50 mM NaCl) and reservoir solution (1.3–
1.6 M ammonium sulfate, 50 mM sodium acetate, pH 4.6, and
20 mM ZnCl
 
2
 
). Diffraction data were recorded at 100
 
 
 
K on LN
 
2
 
flash frozen crystals soaked previously in crystallization buffer
containing 28% ethylene glycol (ID14 EH4; European Synchro-
tron Radiation Facility). The crystals diffract to 2.1-Å resolution
and belong to the trigonal space group P3
 
1
 
21, with unit-cell di-
mension of a 
 
  
 
b 
 
 
 
 97.535 Å and c 
 
 
 
 54.375 Å with one
KIR2DS2 molecule in the asymmetric unit (Table S1 available
at http://www.jem.org/cgi/content/full/jem.20021624/DC1).
Data were processed using DENZO (10) and CCP4 suite (11).
The KIR2DS2 structure was determined by molecular replace-
ment using AmoRe (12). The following KIR coordinates (8–3-Å
data) were used as the initial model: KIR2DL1 (1nkr; reference
9), KIR2DL2 (2dl2, orthorhombic form, and 2dli, trigonal form;
reference 6), and KIR2DL3 (1b6u; reference 7) solved free, and
in complex with their respective HLA-C ligand, KIR2DL2 with
HLA-Cw3 (1efx; reference 8) and KIR2DL1 with HLA-Cw4
(1im9; reference 9). The KIR2DL2 model, excluding the hinge
region Ile
 
101
 
 to Glu
 
105
 
, yielded the clearest solution with a corre-
lation coefficient of 61% and an R factor of 48%. After a rigid
body refinement using CNS (13), the two domains of KIR2DS2
were easily identifiable. Different construction steps using
Turbo-Frodo (14) were alternated with steps of simulated an-
nealing and grouped B-factor refinement using the maximum
likelihood method of CNS, including a bulk solvent correction
and anisotropic B-factor scaling. The final model contains pro-
tein residues Pro
 
8
 
 to Thr
 
200
 
, 82 water molecules, one ethylene
glycol molecule, and one sulfate ion. No electron density was
visible for residues Arg
 
6
 
 and Lys
 
7
 
, which were apparently disor-
dered in the crystals. The side chains of residues Glu
 
35
 
, His
 
56
 
,
Asp
 
57
 
, His
 
85
 
, and His
 
171
 
 do not have any visible electron density
in the 2fo-fc electron density maps contoured at 1
 
 
 
 and were
substituted with alanine residues in the refinement steps. The fi-
nal R
 
cryst
 
 is 22.1% and R
 
free
 
 is 24.7% from 28 to 2.3-Å resolution
(Table S1 available at http://www.jem.org/cgi/content/full/
jem.20021624/DC1).
All KIR three-dimensional structures superpositions were per-
formed using the RIGID and RIGID2 options of Turbo-Frodo
(14), with a fixed cutoff of 8 Å for complete molecule superposi-
tions and a cutoff of 4 Å for the superposition of the separated D1
and D2 KIR domains, respectively. Figures were realized using
Molscript (15), Raster3D (16), and Turbo-Frodo (14).
 
Data Deposition.
 
Atomic coordinates for KIR2DS2 have
been deposited with the Protein Data Bank, Brookhaven Na-
tional Laboratory with the accession code 1m4k.
 
Online Supplemental Material. 
 
The table describes the princi-
pal statistics of data collection and refinement of the KIR2DS2
crystals. Details are available at http://www.jem.org/cgi/content/
full/jem.20021624/DC1.
 
Results and Discussion
 
KIR2DS2 Does Not Interact with HLA-Cw3 Molecules
Recognized by KIR2DL3.
 
We investigated the binding
specificities of KIR2DS2 using tetrameric probes known to
present high avidity binding properties (17). KIR2DL3 and
KIR2DL1 tetramers were also produced in parallel as con-
trols. The integrity of the soluble recombinant biotinylated
KIR monomers was ensured by surface plasmon resonance
as well as by flow cytometry using anti-KIR mAb (GL183
and EB6) and streptavidin-coated beads. In addition, their
monomeric status was verified by analytical and preparative
Superdex gel filtration liquid chromatography. Moreover,
monodispersity of the KIR2DS2 molecules was verified us-
ing dynamic light scattering. As expected, KIR2DL3 tet-
ramers brightly bind HLA-Cw3
 
 
 
 transfectants of the HLA
class I
 
 
 
 lymphoblastoid cell line L721.221 (221.Cw3), but
not parental or 221.Cw4 cells (Fig. 1). Reciprocally,
KIR2DL1 tetramers interact with 221.Cw4 cells, but not
with parental or 221.Cw3 cells (Fig. 1). As a control, the
binding of inhibitory KIR tetramers to their respective
HLA-C ligands is inhibited by the 6a4 anti–HLA class I
mAb (2). Despite the high avidity binding properties of
these KIR tetramers, KIR2DS2 tetramers fail to bind
221.Cw3 and 221.Cw4 cells. In addition, no binding of
KIR2DS2 tetramers was detected on all Asn
 
80
 
 HLA-C
 
 
 
 B
lymphoblastoid cell lines tested, in contrast to the positive
staining systematically obtained with KIR2DL3 tetramers
(unpublished data). These data make it unlikely that the re-
ported failure of KIR2DS2 to interact with HLA-Cw3 is
the consequence of low avidity KIR2DS2/Fc probes used
in the binding assay (3). Thus, our data formally demon-
strate the intrinsic incapacity of KIR2DS2 to recognize
Asn
 
80
 
 HLA-C molecules, at least with a binding mode sim-
ilar to that used by inhibitory KIR2DL2/L3 molecules.
Figure 1. Binding of soluble KIR tetramers to HLA class I transfec-
tants. Cells were incubated with indicated 20 µg/ml tetramers in the ab-
sence or presence of anti–MHC class I mAb 6a4 before flow cytometric
analysis. Determination of cell-surface expression of HLA molecules was
assessed using 6a4 mAb.T
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The putative ligands for KIR2DS2 still remain to be identi-
fied, as KIR2DS2 is involved in susceptibility to autoim-
mune disorders such as rheumatoid vasculitis (18) and pso-
riatic arthritis (19).
 
The Overall Structure of KIR2DS2.
 
The topology of the
KIR2DS2 Ig-like domains is essentially identical to those
of inhibitory KIR, with a 
 
 
 
-sheet containing three antipar-
allel 
 
 
 
-strands (A, B, and E) and a small 
 
 
 
-strand A
 
 
 
, which
makes a switch with the other 
 
 
 
-sheet containing four an-
tiparallel 
 
 
 
-strands (C
 
 
 
CFG). A very short extra 
 
 
 
-strand
(D-strand, residues 54 and 55) adds a 
 
 
 
-strand to the three-
stranded 
 
 
 
-sheets (ABE) of the D1 domain (8). Of note,
there is no extra D 
 
 
 
-strand in KIR2DS2 D2 domain as in
KIR2DL1 and KIR2DL3, in contrast to KIR2DL2 (Fig. 2
A; references 5, 8).
Pairwise superpositions of the six KIR-L structures with
the KIR2DS2 structure revealed (Fig. 2 B) that the root
mean square deviations (rmsds) for 192 equivalent C
 
 
 
 at-
oms are as follows: 2.3 Å for KIR2DL1, 1.8 Å for
KIR2DL2 (trigonal form), 2.0 Å for KIR2DL2 (ortho-
rhombic form), 1.8 Å for the KIR2DL2-A molecule inter-
acting with HLA-Cw3, 1.84 Å for the KIR2DL2-B mole-
cule (the KIR2DL2 molecule free in the crystal complex),
and 2.0 Å for KIR2DL3. One of the notable differences
between KIR-L structures resides in the tertiary packing of
their two extracellular domains. The value of the hinge an-
gle between D1 and D2 domains is variable, demonstrating
some degree of flexibility in the hinge loop region (L4)
from residues 102 to 109 (8). The KIR2DS2 hinge angle
value is 73
 
 
 
, higher than those of free KIR2DL1 (55
 
 
 
) and
complexed KIR2DL1 (66
 
 
 
; reference 9), but lower than
those reported for KIR2DL2 (81
 
 
 
) and KIR2DL3 (78
 
 
 
;
reference 8). A consequence of this few degree variation in
the D1–D2 hinge angle is shown in Fig. 2 B, where
KIR2DS2 D1 and D2 domains do not align with superim-
posed KIR-L D1 and D2 domains. In addition, the total
solvent accessible area buried at the D1–D2 interface of
KIR2DS2 is only 830 Å
 
2
 
, lower than the values reported
in KIR2DL2 (919 Å
 
2
 
), KIR2DL3 (1,050 Å
 
2
 
), and
KIR2DL1 (1,076 Å
 
2
 
; reference 8). The residues found at
the KIR2DS2 D1–D2 interface consist principally of those
conserved in other KIR interdomain hydrophobic core.
Yet, the D1–D2 interface of all inhibitory KIR molecules
contains a conserved interdomain salt bridge Asp
 
98
 
-Arg
 
149
 
that is not conserved in KIR2DS2 structure, where the
NH1 and NH2 groups of the Arg
 
149
 
 side chain make hy-
drogen bonds to a SO
 
4
 
 ion and are distant from the Asp
 
98
 
carbonyl groups from 
 
 
 
8 Å (unpublished data). The su-
perpositions of each separate domain of KIR2 molecules
(Fig. 2 C, D1, and Fig. 2 D, D2) revealed conformational
variabilities in the DE and FG loops of the D1 domain, the
CC
 
 
 
 loop of the D2 domain, and in particular in the L5
 
 
 
loop, a loop defined between 
 
 
 
-strands C
 
 
 
E in D2 (Fig. 2
D). The rmsds for the D1 domains (93–95 equivalent C
 
 
 
atoms within residues 8–102) of KIR2DS2 and the six
other KIR-L molecules are as follows 1.27 Å for
KIR2DL1, 0.96 Å for KIR2DL2 (trigonal form), 1.06 Å
for KIR2DL2 (orthorhombic form), 0.86 Å for
KIR2DL2-A, 0.72 Å for KIR2DL2-B, and 0.94 Å for
KIR2DL3. The rmsds difference between the D2 domains
(91–94 equivalent C
 
 
 
 atoms within residues 103–200) of
KIR2DS2 and the other KIR-L molecules is 0.78 Å for
KIR2DL1, 0.94 Å for KIR2DL2 (trigonal form), 1.2 Å
for KIR2DL2 (orthorhombic form), 1.0 Å for KIR2DL2-A,
0.95 Å for KIR2DL2-B, and 1.0 Å for KIR2DL3. These
rmsds values are similar to those obtained when the D1 and
D2 domains were compared between all KIR-L structures
(unpublished data).
 
The D2 Domain Flexible Loop C
 
 
 
E (L5
 
 
 
 Loop).
 
A dis-
tinctive feature of the KIR2DS2 structure is an almost 90
 
 
 
clockwise rotation of the L5
 
 
 
 loop (the Ser
 
151
 
 to Phe
 
160
 
loop between the 
 
 
 
-strands C
 
 
 
 and E of the D2 domain)
along an axis joining Phe
 
160
 
 C
 
 
 
 and Ser
 
151
 
 C
 
 
 
 (Fig. 2, B
and C). A 14-Å distance separates equivalent residues at
position 157 in KIR2DS2 versus KIR2DL2. In KIR2DL2,
the L5
 
 
 
 loop is poorly stabilized by only two hydrogen
bonds: Thr
 
159
 
-Lys
 
155
 
 and between Gln
 
161
 
-Gly
 
153
 
 (unpub-
lished data). In the case of KIR2DS2, the L5
 
 
 
 loop is highly
stabilized by a network of hydrogen bonds that involves
Thr
 
159
 
, Tyr
 
137
 
, Tyr
 
134
 
, Gly
 
158
 
, Lys
 
155
 
, Asp
 
135
 
, and buried
water molecules (Fig. 3; unpublished data). In addition, a
displacement of the Phe
 
160
 
 benzene ring side chain toward
the external part of the loop shifts the position of the Ser
 
133
 
side chain hydroxyl group to a new position that is 2.0 Å
away from its strictly conserved position in KIR-L mole-
cules. Interestingly, the differences in the position of the
L5
 
 
 
 loop of KIR2DS2 do not result from amino acid differ-
Figure 2. KIR2DS2 crystal
structure and its comparison
with other known KIR struc-
tures. (A) Overall structure of
KIR2DS2 extracellular domains
shown in molecular ribbon rep-
resentation with the  -strands in
green and the coils golden in
color. The two amino acids dif-
ferent between KIR2DS2 and
KIR2DL3 (within the sequence
range 8–200), Tyr45(Y45) and
Glu35(E35), are shown in red
ball-and-stick representation.
The L5  loop between  -strands
C  and E of the D2 domain is
represented in pink. The two
cysteine disulfide bridges are
shown in yellow ball-and-stick
representation. C  trace super-
positions of (B) the complete
KIR molecules (residues 8–200),
(C) the isolated D1 domains (res-
idues 8–102), and (D) the iso-
lated D2 domains (residues 103–
200) are represented as coils with
different colors: KIR2DS2,
green; KIR2DL1, red;
KIR2DL2 (trigonal form), dark
blue; KIR2DL2 (orthorhombic
form), cyan; KIR2DL2 bound to HLA-Cw3 (KIR-A), orange; free
KIR2DL2 (KIR-B) from the same KIR2DL2–HLA-Cw3 complex crys-
tal, marine blue; and KIR2DL3, yellow.T
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ences with KIR2DL2 or KIR2DL3, because the sequence
of the L5  loop is strictly conserved. Instead, they may
be reflecting an inherent loop flexibility made of the
S151AGPKVNGTF160 peptide stretch rich in short amino
acids. The reasons for the particular L5  loop position of
KIR2DS2 are unclear but likely involve KIR2DS2 crystal
packing, as the L5  COOH-terminal half portion interacts
with the C   -strand of another KIR2DS2 monomer (un-
published data).
The L1–L6 Loops in KIR2DS2. 16 amino acids from
six loops (L1–L6) in KIR2DL2 are involved in the interac-
tion with HLA-Cw3 (8). In the D1 domain, four amino
acids (Glu21, Lys44, Gln71, and Asp72) mediate four hydro-
gen bonds and one salt bridge (Glu21-Arg69). In the D2 do-
main, five amino acids (Glu106, Ser133, Asp135, Asp183, and
Glu187) are involved in four hydrogen bonds and three salt
bridges (Glu106-Arg151, Asp135-Arg145, and Asp183-Lys146;
reference 8). Moreover, there are two water-mediated hy-
drogen bonds implicating residues Gln71, Glu187, and Ala8
of the GAV peptide presented by HLA-Cw3. In addition,
hydrophobic contacts contribute to KIR2DL2 and HLA-
Cw3 interaction, and involve 10 KIR2DL2 amino acids:
Phe45, Met70, Gln71, Asp72, Leu104, Tyr105, Ser132, Phe181,
Asp183, and to a lesser extent Ser184. There are only two
amino acid differences between the amino acid sequences
of the extracellular portion of KIR2DS2 and KIR2DL3,
with the Tyr45Phe and Glu35Gln substitutions from
KIR2DS2 to KIR2DL3, and four amino acid differences
between KIR2DS2 and KIR2DL2 (Pro16Arg, Tyr45Phe,
Arg148Cys, and Thr200Ile). Consistent with this high degree
of homology, no significant modifications in the position of
the following 12 key interface amino acids were detected
when KIR2DS2, KIR2DL2, and KIR2DL3 structures
were superimposed: Glu21, Met70, Asp72, Leu104, Tyr105,
Glu106, Ser132, Asp135, Phe181, Asp183, Ser184, and Glu187
(Fig. 4, A–F). As a consequence of these conserved posi-
tions, the failure of KIR2DS2 to bind HLA-Cw3 cannot
be explained by a loss of any of the four salt bridges or by
major alterations in the hydrophobic contacts involved in
KIR2DL2–HLA-Cw3 interaction (unpublished data).
However, the positions of four KIR amino acids (Lys44,
Phe45, Gln71, and Ser133) appear altered between KIR2DS2
and KIR2DL2–HLA-Cw3 complex structures. Lys44 has a
crucial role in the allotypic recognition of Asn80 HLA-C
molecules by KIR2DL2 (1). In KIR2DS2, the position of
Lys44 renders the hydrogen-bonded interaction with Asn80
on HLA-Cw3 unlikely (Fig. 4 B). However, the Lys44 po-
sition is highly variable in the other free KIR-L structures,
probably because of the lack of stabilizing interactions. Po-
sition 45 is of great interest, as it is a natural substitution
(Phe45 by Tyr45) in KIR2DS2 as compared with inhibitory
KIR2DL2-L3. In the KIR2DS2 crystal structure, the Tyr45
benzene ring side chain is clearly visible in the final elec-
tronic density map, but its hydroxyl group is not well-
defined in the structure. Nevertheless, the hydroxyl group
position could be derived from its simple modelization.
When the KIR2DS2 D2 domain is superimposed to the
KIR2DL2–HLA-Cw3 structure, the tip of Tyr45 hydroxyl
group is predicted to be distant from 2.7 Å with the C 
and from 2.5 Å with the CG atoms of HLA-Cw3 Arg79
(Fig. 4 B). Although these distances are short, they do not
support the possibility that Tyr45 in KIR2DS2 could impair
HLA-Cw3 binding because of a lack of sufficient space to
accommodate Tyr45 hydroxyl group and HLA-Cw3  1
helix, as suggested previously (1). However, the hydropho-
bic contacts between Phe45 in KIR2DL2 and Arg75 as well
as Val76 in HLA-Cw3 are predicted to be lost or highly
perturbed for Tyr45 in KIR2DS2 because of the polar na-
ture of the hydroxyl group present on the Tyr45 side chain
(Fig. 4 B). Ser133 is involved in both KIR2DL2–HLA-Cw3
Figure 3. Close-up stereo view of the intramolecular stabilization of
KIR2DS2 L5  loop. Amino acids involved in L5  loop (pink) stabilization
are labeled and represented as sticks with their atom colored according to
their nature.  -strands, green; coils, golden; water, red balls; and hydro-
gen bonds, cyan dotted lines.
Figure 4. Close-up view of the KIR amino acids involved in HLA-
Cw3 recognition. The D1 and D2 domains of the inhibitory KIR2DL2
and KIR2DL3 molecules were superposed to the respective D1 and D2
domains of KIR2DS2. Distances between residues in KIR2DS2 and resi-
dues in a putative HLA-Cw3 ligand are extrapolated from these superpo-
sitions using Turbo-Frodo. Important interacting residues of HLA-Cw3
are represented as sticks in pink; residues from the GAV peptide are in
red; and the residues from other KIR molecules are colored as in Fig. 2.
Hydrogen bonds between KIR2DL2-A (orange) and HLA-Cw3 are in-
dicated by cyan dotted lines (acceptor–donor distances between 2.5 and
3.4 Å), and important water molecules are indicated by red balls. Interact-
ing residues in KIR2DL2/HLA-Cw3 are labeled from the (A) L1 loop,
(B) L2 loop, (C) L3 loop, (D) L4 loop, (E) L5 loop, and (F) L6 loop. T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
937 Saulquin et al. Brief Definitive Report
and KIR2DL1–HLA-Cw4 complexes (8, 9). In KIR2DL2,
Ser133 mediates three hydrogen bonds with the Arg145 side
chain in HLA-Cw3: two with the NH2 group and one
with the NE atom (Fig. 4 E). In the KIR2DS2 structure,
one of these hydrogen bonds is impaired because of the sig-
nificant increase in the distance between the main chain
Ser133 O atom and the NH2 group of Arg145 side chain (Fig.
4 E). This distance is evaluated at 3.9 Å for KIR2DS2, in
contrast with 2.8 Å in the KIR2DL2–HLA-Cw3 crystal
(Fig. 4 E). However, the displacement of Ser133 may likely
be the consequence of the L5  loop particular position (Fig.
3). Finally, Gln71 is also involved in KIR2DL2–HLA-Cw3
interface via two hydrogen bonds: one water-mediated
(water 38) and one with the Ala8 GAV peptide main chain
nitrogen atom. In the KIR2DS2 structure, the fully solvent
accessible Gln71 side chain is positioned in a way that both
hydrogen bonds are not possible (Fig. 4 C). Superpositions
of KIR structures implies Gln71 OE1 in KIR2DS2 to be
distant from 7.4 Å with the Ala8 N atom and from 5.6 Å
with water 38, in contrast to 3.0 Å in both cases for Gln71
OE1 in KIR2DL2–HLA-Cw3 crystal (Fig. 4 C). How-
ever, because no stabilizing interactions of the Gln71 posi-
tion are clearly revealed by the KIR2DS2 structure, we
cannot rule out that Gln71 could take other possible rota-
mer positions. Nevertheless, of the seven possible Gln71
rotamers, the shortest distance measured between the Gln71
OE1 atom and the peptide Ala8 main chain N atom (4.26
Å) is longer than the 3.05-Å distance measured in the
KIR2DL2–HLA-Cw3 complex, and not compatible with
a Gln71–Ala8 interaction.
Conclusions. Our report shows that differences between
KIR2DS2 and KIR2DL2 structures are not major, but
principally result from the presence of the hydroxyl group
of Tyr45 and from the displacement of Gln71 side chain.
Thus, we propose that Tyr45 and Gln71 are likely involved
in the incapacity of KIR2DS2 to bind the HLA-Cw3–pep-
tide complexes recognized by KIR2DL3. For Tyr45, our
results are supported by the Phe45Tyr mutation in
KIR2DL3 that abolishes its binding of to HLA-Cw3, and
the reciprocal Tyr45Phe mutation in KIR2DS2 that restores
to some extent the binding to HLA-Cw3 (3). For Gln71,
the absence of other KIR2DS2 structures obtained from
different crystal lattices is a limitation to the interpretation
of its subtle side chain conformational modification. How-
ever, the predicted loss of the interaction between Gln71
(KIR2DS2) and Ala8 (peptide) is compatible with previous
observations indicating that the loss of a single salt bridge
or a single hydrogen bond destabilizes the electrostatic
and hydrophobic interface between KIR and HLA-C
ligands. Indeed, single replacements of KIR2DL2 residues
(Lys44Met, Tyr105Ala, Asp135His, Asp183Ala, and to a lesser
extent Glu106Ala) are responsible for a large decrease in
HLA-Cw3 binding affinity (8). It is also possible that mod-
ifications observed at positions 44 and 133 contribute to
some extent, alone or in combination, to the failure of
KIR2DS2 to bind to HLA-Cw3. Consistent with the fast
kinetics and the favorable binding entropy of KIR-L inter-
action with HLA-C molecules (20), our results thus em-
phasize the known low tolerance of KIR molecules to sin-
gle mutations at the MHC binding site, and show, at the
atomic resolution level, that KIR and HLA associate essen-
tially as rigid bodies. This mode of KIR recognition
strongly contrasts with the strategy used by TCR and
NKG2D, where conformational changes in receptor bind-
ing loops are necessary for efficient ligand binding (21–23).
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